Lonvi Biosciences, a startup in Shenzhen, China, has built on this foundational research to develop a concentrated PCC1 product in capsule form. Company leaders have described their work as pursuing a major breakthrough in longevity science, with some statements suggesting human lifespans could reach 150 years.
Media reports from late 2025 highlight their optimism, noting progress in refining the compound for potential use. They emphasize targeting inflammatory “zombie cells” while sparing healthy ones.
However, no human clinical trials have yet confirmed these extended lifespan effects. The jump from rodent studies to proven benefits in people remains a significant scientific challenge. Experts in the field maintain cautious optimism – exciting data exists, but large-scale, long-term human evidence is essential before conclusions can be drawn.
